The United States Patent and Trademark Office (USPTO) has issued a design patent, USD1120314S1, to Regeneron Pharmaceuticals, Inc. for a dose delivery device. The patent covers the ornamental design of the device, with one claim, and was filed on November 30, 2022. The official publication date for this patent is March 24, 2026.

This patent grant is a routine event for a company like Regeneron and does not impose new regulatory obligations on other entities. Compliance officers in the pharmaceutical or medical device sectors should note this as a development in intellectual property for a competitor, but no immediate action is required. The patent is a grant of exclusive rights to the assignee, not a regulatory mandate.